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Abstract Surgical resection is often not curative in
patients with acromegaly and long-acting somatostatin ana-
logues(lanreotideoroctreotide)areoftenneeded.This study
assessed the efﬁcacy and safety of self- or partner-adminis-
tration of lanreotide in patients with acromegaly. This was a
six-month, single-arm, open-label study conducted at 13
endocrinology clinics. Fifty-nine patients received deep
subcutaneous lanreotide injections every 28 days. Twelve
patients started on 120 mg lanreotide and forty-seven started
on 90 mg lanreotide. At week 16, the dose was adjusted to
60, 90 or 120 mg based on insulin-like growth factor-1
(IGF-1) levels at week 12. Fifty-nine patients with acro-
megaly either switched from long-acting octreotide (switch;
n = 33) or were somatostatin analogue treatment-naı ¨ve
or not currently taking long-acting octreotide (‘‘other’’;
n = 26). The key endpoints included the percentage of
patients/partners able to self- or partner-inject lanreotide and
those with normal IGF-1 or growth hormone (GH) levels at
week 24/early termination. 100% of patients/partners cor-
rectly self- (n = 41) or partner-injected (n = 18) lanreotide
by week 4. By week 24/early termination, IGF-1 levels were
controlledin93.7% ofswitchand46.2%of‘‘other’’ patients,
while GH levels were controlled in 76.9% and 39.1% of
patients,respectively.BothIGF-1andGHwerecontrolledin
73.1% of switch and 30.4% of ‘‘other’’ patients. Most switch
patients (81%) reported they preferred lanreotide over
long-acting octreotide for future use (P = 0.0001). Self- or
partner-administration of lanreotide is generally well toler-
ated and associated with IGF-1 and GH control in many
lanreotide-naı ¨ve patients with acromegaly.
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Introduction
Most patients with acromegaly present with pituitary
macroadenomas and are, therefore, often not cured by
surgical resection even if the surgery is performed by an
experienced neurosurgeon [1]. Patients with persistent
growth hormone (GH) excess after surgery require further
treatment to reduce serum GH and insulin-like growth
factor-1 (IGF-1) and to attain normal life expectancy [2].
Such treatment may include radiation or pharmacological
therapy. In many instances both treatments may be required
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Furthermore, some studies suggest that primary medical
therapy with long-acting somatostatin analogues (SSAs)
may be appropriate for patients who are at high surgical
risk [4] or prior to surgery as this may improve the surgical
cure rate [5]. SSAs, such as lanreotide (Somatuline

Depot; Ipsen Pharma Biotech, Signes, France) and long-
acting octreotide (octreotide acetate for injectable suspen-
sion, LAR; Sandostatin LAR
 Depot; Novatris, East
Hanover, NJ), inhibit both GH secretion and tumor growth
and are the mainstay of pharmacological therapies for
acromegaly [6, 7].
Lanreotide comes in a long-acting aqueous-gel formu-
lation that is administered via deep subcutaneous injection
every 28 days and provides consistent drug release [8]. It is
provided in a ready-to-use pre-ﬁlled syringe, which obvi-
ates the need for drug reconstitution prior to administration.
The product is volume dependent and not concentration
dependent, with volumes ranging from 0.3–0.5 cc for
delivery of the 60, 90 and 120 mg doses. A previous study
reported that patients with acromegaly receiving a constant
dose of lanreotide for C4 months before screening were
able to successfully self- or partner-administer lanreotide
while maintaining GH and IGF-1 control [9]. We report the
efﬁcacy and safety of self- or partner-administration of
lanreotide in patients with acromegaly who were lanreo-
tide-naı ¨ve and who switched from long-acting octreotide
LAR or who were SSA treatment-naı ¨ve or not currently on
octreotide.
Patients and methods
Study design
This was a 6-month, single-arm, open-label, multicenter
study evaluating the efﬁcacy and safety of self- or partner-
administration of lanreotide in patients with acromegaly.
Patients either switched directly from octreotide LAR
(switch patients) or were SSA treatment naı ¨ve or not cur-
rently on octreotide (‘‘other’’ patients; they could have had
octreotide [4 months prior to enrollment). Patients
receiving dopamine agonist (DA) treatment before the
study were maintained on the same DA dose.
After screening, patients were evaluated at baseline
(week 0) and at weeks 4, 12 and 24. There was an addi-
tional 30-day safety follow-up after the last lanreotide
injection at week 24. Patients received deep subcutaneous
injections of lanreotide every 28 days. Switch patients
were started either on 90 or 120 mg lanreotide, depending
on their prior treatment regimen (e.g., typically 90 mg if
they were on 20 mg octreotide LAR and 120 mg if they
were on 30 mg octreotide LAR). All ‘‘other’’ patients were
started on 90 mg lanreotide except for one patient, who
was on a DA and had previously been on 30 mg octreotide
LAR [4 months prior to enrollment, who started on
120 mg lanreotide. The dose was adjusted to 60, 90 or
120 mg at week 16 based on the patient’s symptoms and
IGF-1 levels at week 12. A schematic illustration of the
study design is shown in Fig. 1.
Patients were given the choice to self- or partner-inject
lanreotide. A ‘‘partner’’ was deﬁned as any person whom
the patient trusted to administer the injection. The local
health care professional demonstrated the injection tech-
nique at week 0 to either the patient or the partner, but the
patient or partner administered all the injections.
Health care professionals completed a questionnaire
assessing the competency of each patient/partner at weeks
0, 4, 8 (if needed) and 24. The competency questionnaire
included questions such as whether or not the patient/
partner followed the instructions given, administered the
injection correctly, administered the complete dose, inser-
ted the needle correctly and inserted the needle to the
appropriate depth. Patients completed a questionnaire
inquiring about acromegaly symptoms at weeks 0, 12, and
24 and an injection diary after each injection. A total score
Fig. 1 Schematic
representation of the study
design
116 Pituitary (2010) 13:115–122
123for symptoms was calculated at each visit based on the
patient’s sweating, snoring, joint pain, headache and fati-
gue. Each symptom was scored as -2 (always), -1 (most
of the time), 0 (sometimes), 1 (rarely) or 2 (never). Switch
patients also completed a convenience questionnaire at
weeks 0 and 24. All questionnaires were made available in
English and Spanish.
The primary endpoint was the percentage of patients/
partners competent to self- or partner-administer lanreotide
at study completion as assessed by the health care pro-
fessional. Secondary assessments included IGF-1 and glu-
cose-suppressed GH levels, symptom and convenience
questionnaires and safety assessments. Safety assessments
included a physical examination, collection of adverse
events (AEs) and laboratory examinations such as a com-
plete blood count (CBC), serum chemistries, thyroid
function tests and urinalysis.
Patients
Fifty-nine patients with acromegaly were recruited by the
local investigators and studied at one of thirteen centers in
the United States. The study protocol was approved by the
local institutional review board of participating centers (see
additional details at: www.clinicaltrials.gov; identiﬁed:
NCT00447499). Informed consent was obtained from the
patients and their partners prior to any study-related
activities.
The study inclusion criteria included suitably motivated
patients with a clinical diagnosis of acromegaly due to a
pituitary tumor and age C18 years. Switch patients also
had to have taken a constant dose of octreotide LAR for at
least 3 months, with serum IGF-1 no higher than 10%
above normal. Switch patients had to have their last
octreotide LAR injection 28–35 days prior to study
enrollment. The study exclusion criteria included pituitary
surgery within 3 months of screening, pituitary radiation
therapy within 3 years of screening, GH receptor antago-
nist therapy within 6 months of screening, current octreo-
tide LAR dose [30 mg every 28 days, renal or hepatic
abnormalities, symptomatic cholelithiasis, poorly con-
trolled diabetes or thyroid disease, pregnancy or breast-
feeding. Contraception was mandatory in patients of
child-bearing potential.
IGF-1 and GH assays
Serum IGF-1 levels were measured with a radioimmuno-
assay after acid-alcohol extraction (RIA-AE) via gamma
counter (Esoterix; Calabasas Hills, CA). The intra-assay
variability of the RIA-AE assay, measured by the coefﬁ-
cient of variation (CV), was 5–14% based on four samples
and ﬁve assay runs of each sample. The inter-assay vari-
ability of the RIA-AE assay was 7–17% based on four
samples and three assay runs of each sample.
Serum GH levels were measured with an immuno-
chemiluminometric assay (ICMA) using an immunometer
(Esoterix; Calabasas Hills, CA). The intra-assay variability
of the ICMA assay, measured by the CV, was 4–14% based
on ten samples and four assay runs of each sample. The
inter-assay variability of the ICMA assay was 7–14% based
on six samples and seventeen assay runs of each sample.
Statistical analyses
For the baseline characteristics, frequency counts and
percents (%) were calculated for sex, previous pituitary
surgery, prior acromegaly medication, SSA treatment and
DA treatment. Mean and standard deviation (SD) were
calculated for age, body mass index (BMI), duration of
acromegaly, time since last pituitary surgery and time since
last SSA treatment. The comparisons between switch and
‘‘other’’ patients were performed using either a chi-square
test or Student’s t-test.
The number and percent of patients who correctly
administered the lanreotide injection at week 24 were
calculated based on the competency questionnaire com-
pleted by the health care professionals for each patient/
partner. For the switch patients, the number and percent of
patients who experienced pain (i.e., not painful, somewhat
painful, moderately painful and very painful) from the
lanreotide injection at week 24 and from the octreotide
LAR injection at week 0 were calculated based on the
convenience questionnaire completed by the switch
patients. The pain experience (not painful) for the two
treatments was compared using a McNemar’s test. For the
preference for future treatment, the number and percent of
switch patients who preferred lanreotide or octreotide LAR
or who had no preference at week 24 or early termination
were calculated based on the convenience questionnaire
completed by the switch patients. A chi-square test was
used to test the hypothesis that more than 50% of switch
patients would prefer one drug over the other for future use.
The biochemical control of glucose-suppressed GH and
IGF-1 were determined at weeks 0 and 24 as: normal IGF-1
and GH\1 lg/L; normal IGF-1 only; GH\1 lg/L only or
none of the above. For each of these four categories, the
number and percent of patients were calculated for switch
and ‘‘other’’ patients. A McNemar’s test was used to test
the change from weeks 0 to 24 within each of the two the
groups. No between group comparisons were performed
because the switch patients had been taking octreotide
LAR for C3 months prior to study enrollment and their
serum IGF-1 levels were no higher than 10% above
normal.
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123Acromegaly symptoms scores were categorized as
symptoms present (scores of -2 to 0) or absent (scores of 1
or 2), and the total score was used to evaluate symptom
control in each patient at weeks 0 and 24. A McNemar’s
test was used to test the change in symptom status from
week 0 to week 24 or early termination within each of the
two the groups using the total score.
AEs were coded using the MedDRA dictionary Version
8.1. Possibly and probably treatment-related AEs occurring
in more than 5% of patients were summarized for switch
and ‘‘other’’ patients. A chi-square test was used to com-
pare the two groups.
Results
Thirty-three switch patients (56% of patients) and 26
‘‘other’’ patients (44%) were enrolled in the study between
June 2007 and May 2008. The baseline characteristics for
all patients are shown in Table 1. As expected, switch
patients had a longer duration of acromegaly than ‘‘other’’
patients. Most patients in both groups had undergone
pituitary surgery.
Seven patients withdrew early from the study. Three
switch patients withdrew early; one patient preferred
octreotide LAR, one patient found the interstate travel
required to attend study visits to be burdensome and one
patient had pituitary tumor progression. Four ‘‘other’’
patients withdrew early from the study; one patient for an
adverse event (irritable bowel syndrome), one patient
refused the week 24 injection, one investigator withdraw a
patient who was suffering from anxiety related to several
incidences of abdominal pain, and the sponsor withdraw a
patient because of concerns about drug transport and dos-
ing reliability during the patient’s overseas travel. All
patients were included in the safety analysis.
Twenty-two switch patients started on 90 mg lanreotide
and two of these patients were on a DA. Eleven switch
patients started on 120 mg lanreotide; ten were switched
from 30 mg octreotide LAR and one was switched from
20 mg octreotide LAR. Three of these patients were on a
DA. At week 16, three switch patients had their dose
adjusted from 90 to 120 mg based on their symptoms and
IGF-1 levels at week 12. The rest of the switch patients
remained on their original dose for the duration of the
study. Twenty-ﬁve ‘‘other’’ patients started on 90 mg lan-
reotide; ﬁve of these patients were on a DA. One ‘‘other’’
patient, who was on a DA and had previously been on
30 mg octreotide LAR, started on 120 mg lanreotide.
Eleven ‘‘other’’ patients had their dose adjusted from 90 to
120 mg and two had their dose adjusted from 90 to 60 mg
based on their symptoms and IGF-1 levels by week 12. The
rest of the ‘‘other’’ patients remained on their original dose
for the duration of the study.
Injection competency and tolerability
Forty-one patients (69.5%) self-injected lanreotide and 18
partners (30.5%) partner-injected lanreotide during the
study. Of the 41 patients who chose to self-inject lanreotide,
27 were switch patients (81.8%) and 14 were ‘‘other’’
patients (53.8%). No patient switched from self-to partner-
injectionoflanreotideduringthestudy,althoughonepatient
had a partner administer the injection at week 4 and
Table 1 Baseline patient characteristics
Characteristic Switch patients (n = 33) Other patients (n = 26)
Female, n (%) 17 (51.5) 13 (50.0)
Age, year, mean (SD) 54.0 (13.0) 51.9 (10.5)
BMI, mean (SD) 32.0 (7.7) 29.7 (5.1)
Duration of acromegaly, year, mean (SD) 10.4 (7.1) 4.3 (4.3)*
Previous pituitary surgery, n (%) 30 (90.9) 22 (84.6)
Time since last pituitary surgery, year, mean (SD) 9.1 (6.6) 3.4 (3.7)

Prior acromegaly medication, n (%) 33 (100.0) 11 (42.3)

Prior SSA treatment, n (%) 33 (100.0) 5 (19.2)

Time since last SSA treatment, days, mean (SD) 32.0 (8.3) 388.0 (373.8)
a
DA treatment, n (%) 5 (15.2) 6 (23.1)
BMI body mass index, SSA somatostatin analogue, DA dopamine agonist
* P = 0.0003 versus switch patients
 P = 0.0006 versus switch patients
 P\0.0001 versus switch patients
a Only 5 patients had received prior SSA treatment in this category (short-acting octreotide [n = 1] or octreotide LAR[4 months prior to study
enrollment [n = 4])
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123self-administered all the other injections. Health care pro-
fessionals reported that 100% of patients/partners were able
to correctly self- or partner-inject lanreotide by week 4 and
continued to correctly administer the injection throughout
the study. Health care professionals also reported that they
were conﬁdent that 100% of patients/partners were able to
follow the instructions given, insert the needle correctly,
achieve the appropriate needle depth and administer the
complete dose by week 4.
More switch patients reported that the injection was not
painful for lanreotide at week 24 versus octreotide LAR at
week 0 (50.0% versus 25.0% of patients, respectively;
P = 0.0201). The rest of the switch patients reported the
lanreotide and octreotide LAR injections as somewhat
painful (43.8 vs. 59.4%), moderately painful (6.3 vs. 6.3%)
or very painful (0.0 vs. 9.4%). More switch patients
reported that the injection was very convenient for lanre-
otide at week 24 versus octreotide LAR at week 0 (75.0 vs.
18.8% of patients, respectively; P = 0.0002). The rest of
the switch patients reported the lanreotide and octreotide
LAR injections as somewhat convenient (15.6 vs. 18.8%),
neither convenient nor inconvenient (3.1 vs. 3.1%),
somewhat inconvenient (3.1 vs. 43.8%) or very inconve-
nient (3.1 vs. 15.6%). Most switch patients reported they
preferred lanreotide over octreotide LAR for future use
(81.3 vs. 12.5%, respectively, 6.2% had no preference;
P = 0.0001).
IGF-1 and GH levels
IGF-1 control was maintained in most switch patients
(Fig. 2). Serum IGF-1 levels were normal in 28 switch
patients (84.8%) at week 0 (i.e., while on octreotide LAR)
and in 30 switch patients (93.7%) at week 24 or early
termination. Serum IGF-1 levels were normal in four
‘‘other’’ patients (15.4%) at week 0 and in 12 ‘‘other’’
patients (46.2%) at week 24 or early termination.
Glucose-suppressed GH levels were obtained in most
patients; they were not obtained in diabetic patients or all
of the early termination patients. Glucose-suppressed GH
levels were\1 lg/L in 21 switch patients (70.0%) at week
0 and in 20 switch patients (76.9%) at week 24 or early
termination. Glucose-suppressed GH levels were\1 lg/L
in only three ‘‘other’’ patients (12.0%) at week 0 and in 9
‘‘other’’ patients (39.1%) at week 24 or early termination.
Forty-nine patients had both IGF-1 and glucose-sup-
pressed GH values at week 24 or early termination. Self- or
partner-administration of lanreotide was associated with
both IGF-1 and GH control in many patients with acro-
megaly (73.1% of switch patients and 30.4% of ‘‘other’’
patients at week 24 or early termination versus 63.3% and
4.0% at week 0, respectively; Table 2).
Discordant IGF-1 and glucose-suppressed GH levels
\1 lg/L were observed in 11 of 49 patients (22.4%) who
had both values available at week 24 or early termination
(Table 2). Six switch patients (23.1%) had discordant
IGF-1 and glucose-suppressed GH levels\1 lg/L at week
24 or early termination; ﬁve of these switch patients
(83.3%) had normal IGF-1 levels only. Five ‘‘other’’
patients (21.7%) had discordant IGF-1 and glucose-
suppressed GH levels\1 lg/L at week 24 or early termi-
nation; three of these ‘‘other’’ patients (60.0%) had normal
IGF-1 levels only. Discordant IGF-1 and fasting GH levels
Fig. 2 Serum IGF-1 concentrations at baseline versus week 24 or
early termination for switch patients who had these values available at
both time points (n = 32)
Table 2 Normal IGF-1 or glucose-suppressed GH levels at weeks 0
and 24 or at early termination
Switch patients
(n = 33)
Other patients
(n = 26)
Week 0, n (%)
Normal IGF-1 and GH\1 lg/L 19/30 (63.3) 1/25 (4.0)
Normal IGF-1 and GH[1 lg/L 6/30 (20.0) 3/25 (12.0)
Elevated IGF-1 and GH\1 lg/L 2/30 (6.7) 2/25 (8.0)
Elevated IGF-1 and GH[1 lg/L 3/30 (10.0) 19/25 (76.0)
Week 24 or early termination, n (%)
Normal IGF-1 and GH\1 lg/L 19/26 (73.1) 7/23 (30.4)*
Normal IGF-1 and GH[1 lg/L 5/26 (19.2) 3/23 (13.0)
Elevated IGF-1 and GH\1 lg/L 1/26 (3.8) 2/23 (8.7)
Elevated IGF-1 and GH[1 lg/L 1/26 (3.8) 11/23 (47.8)
Glucose-suppressed GH levels were not obtained in diabetic patients
and were not obtained in all of the early termination patients
* P = 0.0143 versus week 0
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123\1 lg/L were observed in 18 of 54 patients (33.3%) who
had both values at week 24 or early termination. Twelve
switch (41.4%) and six ‘‘other’’ patients (24.0%) had dis-
cordant IGF-1 and fasting GH levels\1 lg/L.
Symptoms
Symptom control was maintained in most switch patients
and symptoms improved in many ‘‘other’’ patients from
week 0 to 24 or early termination (based on the change in
symptom status for the symptoms scores for ‘‘other’’
patients, P = 0.0075; Fig. 3).
Safety
Self- or partner-administration of lanreotide was generally
well tolerated. The most common AE was diarrhea, which
was less common among switch than ‘‘other’’ patients.
There were no unexpected treatment-related AEs. The
possibly/probably treatment-related AEs are shown in
Table 3.
There were seven serious AEs in ﬁve patients. One
serious AE was considered possibly or probably treatment-
related by the physician: a switch patient with pancreatitis and abdominal pain 1 day after the last lanreotide injection
who recovered with no permanent damage. Six serious AEs
in four patients were considered unrelated to treatment by
the physician: one switch patient developed melanoma; one
switch patient had poorly controlled diabetes, worsening
obesity and worsening osteoarthritis; one switch patient
had worsening chronic back pain and one ‘‘other’’ patient
developed thyroid cancer.
Discussion
Acromegaly is a chronic disease that often requires long-
term pharmacological treatment in patients with persistent
GH excess after surgery. For many patients, such as those
with busy schedules, limited mobility or who live a long
distance from the health care professional’s ofﬁce, the
possibility of self- or partner-administration of therapy is
important as it may decrease the need for frequent trips to
the ofﬁce. For this reason, the use of drug formulations that
do not require reconstitution by a health care professional
has increased in recent years.
The current study evaluated the efﬁcacy and safety of
self- or partner-administration of lanreotide in lanreotide-
naı ¨ve patients who either switched directly from another
SSA (octreotide LAR) or were SSA treatment-naı ¨ve or not
currently on octreotide LAR. This study found that 100%
of patients/partners were able to correctly self- or partner-
inject lanreotide and that no patient reported a preference
to receive the injection by a health care professional.
l
I
Fig. 3 The percentage of patients with worse, similar or improved
acromegaly symptoms from week 0 to 24 or early termination. A total
score for symptoms was calculated at each visit based on the patient’s
sweating, snoring, joint pain, headache and fatigue. Each symptom
was scored as -2 (always), -1 (most of the time), 0 (sometimes), 1
(rarely) or 2 (never). *P = 0.0075 for the change in symptom status
for ‘‘other’’ patients from symptoms present (scores of -2t o0 )t o
absent (scores of 1 or 2)
Table 3 Possibly or probably treatment-related AEs (occurring in
[5% of patients)
Switch
patients
(n = 33),
n (%)
Other
patients
(n = 26),
n (%)
Patients reporting C1 adverse event 18 (55) 24 (92)*
Diarrhea 9 (27) 17 (65)

Headache 7 (21) 3 (12)
Abdominal pain upper 3 (9) 5 (19)
Abdominal pain 2 (6) 6 (23)
Nausea 4 (12) 4 (15)
Injection site pain 4 (12) 2 (8)
Injection site irritation 2 (6) 3 (12)
Alopecia 1 (3) 3 (12)
Flatulence 2 (6) 2 (8)
Injection site pruritus 1 (3) 3 (12)
Serious adverse event: pancreatitis
(resolved)
1 (3) –
* P = 0.0015 versus switch patients;
 P = 0.0034 versus switch
patients
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123Accordingly, the majority of patients reported they pre-
ferred lanreotide over octreotide LAR for future use. A
previous study also found that patients who were on lan-
reotide for at least 4 months and who received injections
by a health care professional were able to successfully
switch to self- or partner-administer lanreotide while
maintaining GH and IGF-1 control [9].
More patients elected self-injection than partner-injec-
tion in this study, which emphasizes the convenience of
this approach versus required visits to a health care pro-
fessional. There was no gender preference for self-admin-
istration in this study (69% of the men and 70% of the
women self-administered lanreotide). Overall, the costs of
the two medications are very similar with minor variations
depending upon insurance coverage. However, the ability
of a patient to self- or partner-inject means that they do not
have to travel to a health care facility for injections, with a
reduction in transportation, parking, and ofﬁce cost, and
avoidance of lost time from work.
As one might expect, the duration of acromegaly was
longer in switch than in ‘‘other’’ patients, since they were
previously on a ﬁxed dose of SSA, and their IGF-1 and GH
control was maintained with lanreotide treatment in this
study. IGF-1 and GH control was lower in the ‘‘other’’
patients because these patients were not pre-selected to be
responsive to SSAs. Indeed, the 46.2% of ‘‘other’’ patients
with normalization of serum IGF-1 levels by week 24 or
early termination was similar to the efﬁcacy reported pre-
viously for lanreotide in patients with acromegaly [10]
even with the short duration of follow-up. Consistent with
the hormonal data, the symptoms of acromegaly did not
change signiﬁcantly in the switch patients and improved in
the ‘‘other’’ patients in this study.
Previous studies have reported discordant serum IGF-1
and GH levels in patients with acromegaly on SSA thera-
pies [11–13]. Discordant values were commonly reported
as normal IGF-1 and either high random or post-glucose
GH levels, although the reverse has also been reported. A
recent study by Carmichael et al. [12] found that glucose-
suppressed GH levels (\2 lg/L when tested before 1998,
and \1 lg/L afterwards) were discordant with serum
IGF-1 in 48% of patients receiving SSAs. The authors
concluded that post-glucose GH levels are not useful for
the evaluation of disease control in patients receiving
SSAs. Another study found discordant serum IGF-1 and
glucose-suppressed GH levels in 41% of patients receiving
octreotide LAR [13]. In the current study, discordant IGF-1
and GH levels at week 24 or at early termination were
observed in 11 of 49 patients who had both these values
available (22.4% of patients). Although the reason for the
observed difference in discordant IGF-1 and GH levels
noted in the current versus previous studies is not clear, one
possible explanation may be the use of a single SSA in the
current study. Another possible explanation is that the
different settings, clinical trial versus retrospective review,
may inﬂuence the timing of the oral glucose tolerance test
(OGTT) relative to the injection, with patients in the cur-
rent study undergoing OGTT in a more timely fashion
relative to the last SSA injection compared with the vari-
able timing typically encountered in clinical practice. The
current study, however, was not powered to make this
determination. Independent of the explanation for this
difference, the data from the current study suggest that
post-glucose OGTT might still have a value in assessing
disease control in patients with acromegaly on SSAs.
In conclusion, this study found that self- or partner-
administration of lanreotide was generally well tolerated
and associated with control of IGF-1 and GH levels in
many lanreotide-naı ¨ve patients with acromegaly. The most
common AE was diarrhea, which was less common among
switch than ‘‘other’’ patients. Self- or partner-administra-
tion requires instruction by an experienced health care
professional, who must supervise the ﬁrst injection to
ensure proper administration. This self-administration
approach may give patients the option to decrease their
trips to their health care professional.
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